Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 4/2019

01-11-2019 | Diabetic Retinopathy | Original Article

MicroRNA-423 may regulate diabetic vasculopathy

Authors: Arnon Blum, Ari Meerson, Hanan Rohana, Hanin Jabaly, Nahul Nahul, Dorina Celesh, Olga Romanenko, Snait Tamir

Published in: Clinical and Experimental Medicine | Issue 4/2019

Login to get access

Abstract

To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.
Literature
1.
2.
Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101:2087–92.PubMed
3.
Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Profiling of circulating microRNAs: from single biomarkers to rewired networks. Cardiovasc Res. 2012;93:555–62.PubMed
4.
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–33.PubMedPubMedCentral
5.
Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–33.PubMedPubMedCentral
6.
Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E, et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes mellitus that change with insulin sensitization. Diabetes Care. 2014;37(5):1375–83.PubMed
7.
Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature. 2017;542(7642):450–5.PubMedPubMedCentral
8.
Meerson A, Ploug T. Assessment of six commercial plasma small RNA isolation kits using qRT-PCR and electrophoretic separation: higher recovery of microRNA following ultracentrifugation. Biol Methods Protoc. 2016;1:bpw003.PubMedPubMedCentral
9.
Pezzolesi MG, Satake E, McDonnell KP, Major M, Smiles AM, Krolewski AS. Circulating TGF-β1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes. Diabetes. 2015;64:3285–93.PubMedPubMedCentral
10.
Jones A, Danielson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, Das S, Macartney-Coxson D. miRNA signatures of insulin resistance in obesity. Obesity (Silver Spring). 2017;25:1734–44.
11.
Meerson A, Najjar A, Saad E, Sbeit W, Barhoum M, Assy N. Sex differences in plasma microRNA biomarkers of early and complicated diabetes mellitus in Israeli Arab and Jewish Patients. Non-Coding RNA. 2019;5:32.PubMedCentral
12.
Zampetaki A, Willeit P, Burr S, Yin X, Langley SR, Kiechl S, Klein R, Rossing P, Chaturvedi N, Mayr M. Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes. Diabetes. 2016;65:216–27.PubMed
13.
Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al. Plasma microRNA profiling reveals loss of endothelial MiR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810–7.PubMed
14.
Jimenez-Lucena R, Rangel-Zúñiga OA, Alcalá-Díaz JF, Lopez-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano E, Caballero-Villarraso J, Delgado-Lista J, Castaño JP, et al. Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORDIOPREV study. Mol Ther Nucl Acids. 2018;12:146–57.
15.
Seyhan AA, Nunez Lopez YO, Xie H, Yi F, Mathews C, Pasarica M, Pratley RE. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. Sci Rep. 2016;6:31479.PubMedPubMedCentral
16.
de Candia P, Spinetti G, Specchia C, Sangalli E, La Sala L, Uccellatore A, Lupini S, Genovese S, Matarese G, Ceriello A. A unique plasma microRNA profile defines type 2 diabetes progression. PLoS ONE. 2017;12:e0188980.PubMedPubMedCentral
17.
Hirota K, Keino H, Inoue M, Ishida H, Hirakata A. Comparisons of microRNA expression profiles in vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253:335–42.PubMed
18.
Blum A, Yehuda H, Geron N, Meerson A. Elevated levels of miR-122 in serum may contribute to improved endothelial function and lower oncologic risk following bariatric surgery. Isr Med Assoc J. 2017;19:620–4.PubMed
19.
Pastukh N, Meerson A, Kalish D, Jabaly H, Blum A. Serum miR-122 levels correlate with diabetic retinopathy. Clin Exp Med. 2019;2:255–60.
20.
Wang X, Sundquist J, Zöller B, Memon AA, Palmér K, Sundquist K, Bennet L. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE. 2014;9:e86792.PubMedPubMedCentral
21.
Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, Dong Q, Pang Z, Guan Q, Gao L, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48:61–9.PubMed
22.
Flowers E, Kanaya AM, Fukuoka Y, Allen IE, Cooper B, Aouizerat BE. Preliminary evidence supports circulating microRNAs as prognostic biomarkers for type 2 diabetes. Obes Sci Pract. 2017;3:446–52.PubMedPubMedCentral
23.
McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes. 2011;60:1314–23.PubMedPubMedCentral
24.
Carreras-Badosa G, Bonmatí A, Ortega F-J, Mercader J-M, Guindo-Martínez M, Torrents D, Prats-Puig A, Martinez-Calcerrada J-M, Platero-Gutierrez E, De Zegher F, et al. Altered circulating miRNA expression profile in pregestational and gestational obesity. J Clin Endocrinol Metab. 2015;100:E1446–56.PubMed
25.
Farr RJ, Januszewski AS, Joglekar MV, Liang H, McAulley AK, Hewitt AW, Thomas HE, Loudovaris T, Kay TWH, Jenkins A, et al. A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci Rep. 2015;5:10375.PubMedPubMedCentral
26.
27.
Graeber TG, Peterson JF, Tsai M, Monika K, Fornace AJ, et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 1994;14:6264–77.PubMedPubMedCentral
28.
Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol. 2001;21:1297–310.PubMedPubMedCentral
29.
Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 2004;18:2183–94.PubMedPubMedCentral
30.
Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, et al. HIF-1 alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004;23:1949–56.PubMedPubMedCentral
31.
Kovacs B, Lumayag S, Cowan C, Xu S. microRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Investig Ophthalmol Vis Sci. 2011;52:4402–9.
32.
Blum A, Socea D, Ben-Shushan RS, Keinan-Boker L, Naftali M, Segol G, Tamir S. A decrease in VEGF and inflammatory markers is associated with diabetic proliferative retinopathy. Eur Cytokine Netw. 2012;23(4):158–62.PubMed
33.
Li Q, Yu Q, Na R, Liu B. MiR-423-5p inhibits human cardiomyoblast proliferation and induces cell apoptosis by targeting Gab 1. Int J Clin Exp Pathol. 2016;9(9):8953–62.
34.
35.
Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem. 1994;63:175–95.PubMed
36.
Caimi G, Hopps E, Montana M, Noto D, Canino B, Lo Presti R, et al. Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. Diabetes Metab Syndr. 2012;6(3):132–5.PubMed
37.
Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium. 2004;11(2):89–97.PubMed
38.
Pacher P, Beckman JS, Liauder L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87(1):315–424.PubMed
39.
Beckman JP, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem Soc Trans. 1993;21(2):330–4.PubMed
40.
Honing ML, Morrison PJ, Banga JD, Stroes ES, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev. 1998;14(3):241–9.PubMed
41.
Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010;459(6):923–39.PubMed
42.
Brownlee M. The pathology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.PubMed
43.
Pitocco D, Zaccardi F, Di Stasio E, Romitelli SA, Santini SA, Zuooi C, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010;7(1):15–25.PubMedPubMedCentral
44.
Adela R, Nethi SK, Bagul PK, Barui AK, Mattapally S, Kuncha M, et al. Hyperglycemia enhances nitric oxide production in diabetes: a study from South Indian patients. PLoS ONE. 2015;10(4):e0125270.PubMedPubMedCentral
45.
Aydin A, Orhan H, Sayal A, Ozata M, Sahin G, Ismer A. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin Biochem. 2001;34(1):65–70.PubMed
46.
Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab. 2003;88(4):1624–8.PubMed
47.
Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF. Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. Pediatr Diabetes. 2006;7(1):51–9.PubMed
48.
Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Martini F, Scaglione GL, et al. Role of asymmetric dimethyl L arginine (ADMA) and nitrite/nitrate (NOx) in the pathogenesis of oxidative stress in female subjects with uncomplicated type 1 diabetes mellitus. Diabetes Res Clin Pract. 2009;86(3):173–6.PubMed
49.
Daimon M, Sugiyama K, Saitoh H, Yamaguchi A, Hirata A, Ohnuma H. Increase in serum ceruloplasmin levels is correlated with a decrease of serum nitric oxide levels in type 2 diabetes. Diabetes Care. 2000;23(4):559–60.PubMed
50.
Krause J, Rodrigues-Krause J, O’Hagan C, De Vito G, Boreham C, Susta D, et al. Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study. Metab, Clin Exp. 2012;61(11):1528–37.
51.
Shiekh GA, Ayub T, Khan SN, Dar R, Andrabi KI. Reduced nitrate level in individuals with hypertension and diabetes. J Cardiovasc Dis Res. 2011;2(3):172–6.PubMedPubMedCentral
52.
Yang P, Cao Y, Li H. Hyperglycemia induces inducible nitric oxide synthase gene expression and consequent nitrosative stress via c-Jun N-terminal kinase activation. Am J Obstet Gynecol. 2010;203(2):185 e5-11.PubMed
53.
Zhang X, Fu Y, Xu X, Li M, Du L, Han Y, et al. PERK pathway are involved in NO-induced apoptosis in endothelial cells cocultured with RPE under high glucose conditions. Nitric Oxide. 2014;40:10–6.PubMed
54.
Cai S, Khoo J, Channon KM. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res. 2005;65(4):823–31.PubMed
55.
Smukler SR, Tang L, Wheeler MB, Salapatek AM. Exogenous nitric oxide and endogenous glucose-stimulated beta-cell nitric oxide augment insulin release. Diabetes. 2002;51(12):3450–60.PubMed
56.
Kurohane Kaneko Y, Ishikawa T. Dual role of nitric oxide in pancreatic beta cells. J Pharmacol Sci. 2013;123(4):295–300.PubMed
57.
Eizirik DL, Flodstrom M, Karlsen AE, Welsh N. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia. 1996;39(8):875–90.PubMed
58.
Cha HN, Kim YM, Kim JY, Kim YD, Song IH, Min KN, et al. Lack of inducible nitric oxide synthase does not prevent aging-associated insulin resistance. Exp Geront. 2010;45(9):711–8.
59.
Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, et al. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation. 2004;109:2986–92.PubMed
60.
Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide related but not oxidative stress-mediated mechanisms. Diabetes. 2007;56:1559–68.PubMed
61.
Krankel N, Adams V, Linke A, Gielen S, Erbs S, Lenk K, et al. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol. 2005;25:698–703.PubMed
62.
Callaghan MJ, Ceradini DJ, Gurtner GC. Hyperglycemia-induced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal. 2005;7:1476–82.PubMed
63.
Ma FX, Zhou B, Chen Z, Ren Q, Lu SH, Sawamura T, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res. 2006;47:1227–37.PubMed
64.
Kuki S, Imanishi T, Kobayashi K, Matsuo Y, Obana M, Akasaka T. Hyperglycemia accelerated endothelial progenitor cell senescence via the activation of p38 mitogen-activated protein kinase. Circ J. 2006;70:1076–81.PubMed
65.
Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, Widder JD, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 2007;56:666–74.PubMed
66.
Blum A, Socea D, Pastukh N, Jabaly H. Colony forming unites-endothelial progenitor cells: a surrogate marker for diabetic retinopathy and high cardiovascular mortality rate. Int J Pharma Res Rev. 2016;5(5):57–62.
67.
Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999;41:773–80.PubMed
68.
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988–95.PubMed
69.
Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. J Biol Chem. 1995;270:6729–33.PubMed
70.
Cudmore M, Ahmed S, Al-Ani B, Hewett P, Ahmed S, Ahmed A. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem Biophys Commun. 2006;345(4):1275–82.
71.
Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevera I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wojtowicz A, Szuba A, Cooke JP. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Artherioscler Thromb Vasc Biol. 2000;20(3):659–66.
72.
73.
Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? JCell Biochem. 2017;118(11):3577–85.
Metadata
Title
MicroRNA-423 may regulate diabetic vasculopathy
Authors
Arnon Blum
Ari Meerson
Hanan Rohana
Hanin Jabaly
Nahul Nahul
Dorina Celesh
Olga Romanenko
Snait Tamir
Publication date
01-11-2019
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 4/2019
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00573-8

Other articles of this Issue 4/2019

Clinical and Experimental Medicine 4/2019 Go to the issue

Original Article

MAT2B mediates invasion and metastasis by regulating EGFR signaling pathway in hepatocellular carcinoma

Original Article

IL-8 gene locus is associated with risk, severity and 28-day mortality of sepsis in a Chinese population

Original Article

NK and NKT-like cells in granulomatous and fibrotic lung diseases

Original Article

Serum lipidome screening in patients with stage I non-small cell lung cancer

Original Article

Severe thrombocytopenia in pregnancy: a case series from west China

Original Article

Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits